Author Nogami, Naoyuki| Hotta, Katsuyuki| Kuyama, Shoichi| Kiura, Katsuyuki| Takigawa, Nagio| Chikamori, Kenichi| Shibayama, Takuo| Kishino, Daizo| Hosokawa, Shinobu| Tamaoki, Akihiko| Harita, Shingo| Tabata, Masahiro| Ueoka, Hiroshi| Shinkai, Tetsu| Tanimoto, Mitsune|
Published Date 2011-10
Publication Title Lung Cancer
Volume volume74
Issue issue1
Content Type Journal Article
Author Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-01
Publication Title Lung Cancer
Volume volume83
Issue issue1
Content Type Journal Article
Author Ochi, Nobuaki| Takigawa, Nagio| Harada, Daijiro| Yasugi, Masayuki| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-03-10
Publication Title Experimental Cell Research
Volume volume322
Issue issue1
Content Type Journal Article
Title Alternative A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy
FullText URL 127_127.pdf
Author Kiura, Katsuyuki| Hotta, Katsuyuki| Sato, Akiko| Ohashi, Kadoaki| Ninomiya, Takashi| Minnami, Daisuke| Tabata, Masahiro| Kubo, Toshio| Kato, Yuka| Hirata, Taizo|
Keywords 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine
Publication Title 岡山医学会雑誌
Published Date 2015-08-03
Volume volume127
Issue issue2
Start Page 127
End Page 132
ISSN 0030-1558
Related Url isVersionOf https://doi.org/10.4044/joma.127.127
language 日本語
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
DOI 10.4044/joma.127.127
NAID 130005096256
JaLCDOI 10.18926/AMO/54508
FullText URL 70_4_299.pdf
Author Wada, Koichiro| Uehara, Shinya| Ishii, Ayano| Sadahira, Takuya| Yamamoto, Masumi| Mitsuhata, Ritsuko| Takamoto , Atsushi| Araki, Motoo| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
Keywords probiotics lactobacilli Lactobacillus crispatus urinary tract infection vaginal suppository
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 299
End Page 302
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549677
Web of Science KeyUT 000384748600012
JaLCDOI 10.18926/AMO/54514
FullText URL 70_4_327.pdf
Author Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
Abstract A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
Keywords metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 327
End Page 330
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549683
Web of Science KeyUT 000384748600018
JaLCDOI 10.18926/AMO/54507
FullText URL 70_4_295.pdf
Author Araki, Motoo| Wada, Koichiro| Mitsui, Yosuke| Kubota, Risa| Yoshioka, Takashi| Ariyoshi, Yuichi| Kobayashi, Yasuyuki| Kitagawa, Masashi| Tanabe, Katsuyuki| Sugiyama, Hiroshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
Keywords end-stage renal disease immunosuppression kidney transplantation
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 295
End Page 297
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549676
Web of Science KeyUT 000384748600011
FullText URL J_Thorac_Oncol_201907017.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords ALK G1202R Alectinib Amphiregulin MET NSCLC
Published Date 2019-07-30
Publication Title Journal of Thoracic Oncology
Volume volume14
Issue issue11
Publisher Elsevier
Start Page 2009
End Page 2018
ISSN 15560864
NCID AA12058455
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
File Version author
PubMed ID 31374369
DOI 10.1016/j.jtho.2019.07.017
Web of Science KeyUT 000492678300025
Related Url isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017
FullText URL fulltext.pdf figs.pdf tables.pdf
Author Itano, Junko| Higo, Hisao| Ohashi, Kadoaki| Makimoto, Go| Nishii, Kazuya| Hotta, Katsuyuki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords osimertinib drug-induced ILD reversed halo sign organizing pneumonia pattern re-administration
Published Date 2020-03-15
Publication Title Internal Medicine
Volume volume59
Issue issue6
Publisher The Japanese Society of Internal Medicine
Start Page 823
End Page 828
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version author
PubMed ID 31787696
DOI 10.2169/internalmedicine.3689-19
Web of Science KeyUT 000521137500011
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3689-19
FullText URL fulltext.pdf
Author Kano, Hirohisa| Ichihara, Eiki| Harada, Daijiro| Inoue, Koji| Kayatani, Hiroe| Hosokawa, Shinobu| Kishino, Daizo| Watanabe, Kazuhiko| Ochi, Nobuaki| Oda, Naohiro| Hara, Naofumi| Ninomiya, Kiichiro| Hotta, Katsuyuki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords immune checkpoint inhibitor non-small cell-lung cancer PD-L1 pembrolizumab poor performance status
Published Date 2020-07-29
Publication Title Cancer Science
Publisher Wiley
ISSN 1347-9032
NCID AA11808050
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 32726470
DOI 10.1111/cas.14590
Web of Science KeyUT 000562490200001
Related Url isVersionOf https://doi.org/10.1111/cas.14590